Key facts
- It has raised $21.0M; the latest was Grant ($2.6M) in Feb 2025.
- Notable investors include Bpifrance, Agoranov, M Ventures, Omnes Capital, Debiopharm Innovation Fund — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Iktos
- ·The full record, as it builds
Funding rounds
No funding rounds for Iktos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iktos
Developer of a drug discovery platform intended to combine generative AI and robotics to tackle the inefficiencies of traditional drug development processes. The company's platform specializes in artificial intelligence and robotic applied to research in medicinal chemistry and new drug design, applied to chemical research, specifically medicinal chemistry, and new drug design developed several proprietary and innovative systems based on AI, helping researchers to identify drug candidates in their research and development program.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2016
- Employees
- 81
- Website
- iktos.ai/
- Ownership
- Privately Held (backing)
Iktos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iktos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iktos in its N-PORT filings yet. We sweep new filings monthly.